Moderate-to-Severe Hot Flashes With Intact Uterus: Next Step When Non-Hormonal Prescription Medications Have Not Controlled Vasomotor Symptoms

Clinical Scenario

This protocol addresses a woman experiencing moderate to severe hot flashes (vasomotor symptoms) who has an intact uterus and no contraindication to estrogen therapy.

Prior Treatment — Insufficient Response

A preceding line of non-hormonal prescription medications — including agents such as venlafaxine, desvenlafaxine, paroxetine, fluoxetine, citalopram, escitalopram, clonidine, gabapentin, or pregabalin — did not achieve adequate reduction of vasomotor symptoms (hot flashes). This protocol represents the clinical step taken after that failure.

Treatment Approach (Overview)

Management at this stage centres on a structured behavioural therapy — the full protocol specifies the intervention, its place in the treatment sequence, and all relevant clinical guidance.

Clinical Goal

Reduction of vasomotor symptoms (hot flashes).

Instant Access to Structured Evidence-Based Regimens

References

Moderate to severe hot flashes: MHT is the gold standard and best therapy for reduction of VMS (Tables 1-5), followed by non-hormonal prescription medications (Tables 6, 7) as a second choice.

Women with a uterus can use either systemic estrogen combined with a progestogen (EPT) or the tissue-selective estrogen complex (conjugated equine estrogens and bazedoxifene).

Cognitive behavioural therapy may be helpful.

Cognitive behavioural therapy and, to a lesser extent, clinical hypnosis have been shown to be effective in reducing vasomotor symptoms.

View source ↗